Contact Us

Case Review Form
*    Denotes required field.

Describe accident or indicate name of drug or device

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Xarelto Lawsuits Increase in Number with No Sign of Abatement

Sep 29, 2016

Judge Eldon Fallon has extended the filing deadline for certain classes of plaintiffs in In Re Xarelto Product Liability Litigation MDL #2592. The first bellwether trials for those cases are scheduled for February 2017.

Without exception these cases allege that the Xarelto manufacturer, Janssen Pharmaceuticals, and distributors, Johnson & Johnson (J&J) in the United States, and Bayer overseas, knowingly put patients at risk for uncontrollable bleeding.

The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 as a more convenient, "new generation" of anticoagulant to be an alternative to the established Coumadin. However, thousands of patients have come forward complaining of suffering from serious life-threatening side effects.

Janssen opted not to warn health professionals or the public about the dangers of the relatively new medication. Profits for Xarelto soared, as celebrities including golf legend Arnold Palmer, endorsed the drug on TV commercials. Numerous plaintiffs in their Xarelto lawsuits maintain that Janssen purposely used misleading marketing and advertising to promote their blood thinner.

Additionally, an investigation was conducted regarding the use of a defective medical device in Xarelto clinical trials. The defective device may have resulted in false data by showing Xarelto to be more effective that it really was. This data was sent to reputable medical journals according to the New York Times. Plaintiffs in the Xarelto lawsuit claim that the respected New England Journal of Medicine left out critical data in the drug's analysis.

Xarelto had nearly $2 billion in sales in the United States and is the best seller in the new category of drugs seeking to replace warfarin (Coumadin), according to the Times.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo